Literature DB >> 12628049

Treatment of Raynaud's phenomenon: new insights and developments.

Ariane L Herrick1.   

Abstract

Although certain broad principles of treatment apply to all patients with Raynaud's phenomenon, the exact approach will vary depending on the nature and severity of the underlying digital vascular problem. Advances in the understanding of the pathophysiology of Raynaud's phenomenon are directing new lines of therapy. This review considers general (nonpharmacologic) measures, the different types of drug therapy, and the role of surgery. Recent advances in the use of more conventional treatments, such as calcium channel blockers, are discussed and also newer agents that are currently being researched, for example, endothelin-1 receptor antagonists and nitric oxide donors. The necessity of prompt assessment and treatment of acute digital ischemia, which is a medical emergency, is highlighted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12628049     DOI: 10.1007/s11926-003-0046-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  50 in total

1.  Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma.

Authors:  R R Freedman; R Girgis; M D Mayes
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

2.  Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; J H Korn; M E Csuka; T A Medsger; N F Rothfield; M Ellman; R Martin; D H Collier; A Weinstein; D E Furst; S A Jimenez; M D Mayes; P A Merkel; B Gruber; L Kaufman; J Varga; P Bell; J Kern; P Marrott; B White; R W Simms; A C Phillips; J R Seibold
Journal:  Arthritis Rheum       Date:  1998-04

3.  Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin.

Authors:  S A Cotton; A L Herrick; M I Jayson; A J Freemont
Journal:  J Pathol       Date:  1999-10       Impact factor: 7.996

4.  Adventitial stripping: a digit saving procedure in refractory Raynaud's phenomenon.

Authors:  A M Yee; R N Hotchkiss; S A Paget
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

5.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Authors:  R N Channick; G Simonneau; O Sitbon; I M Robbins; A Frost; V F Tapson; D B Badesch; S Roux; M Rainisio; F Bodin; L J Rubin
Journal:  Lancet       Date:  2001-10-06       Impact factor: 79.321

6.  Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: a description of treatment protocol and evaluation of results.

Authors:  M M Tomaino; R J Goitz; T A Medsger
Journal:  Microsurgery       Date:  2001       Impact factor: 2.425

7.  A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis.

Authors:  A L Herrick; S Hollis; D Schofield; F Rieley; A Blann; K Griffin; T Moore; J M Braganza; M I Jayson
Journal:  Clin Exp Rheumatol       Date:  2000 May-Jun       Impact factor: 4.473

8.  Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  M E Anderson; T L Moore; S Hollis; M I V Jayson; T A King; A L Herrick
Journal:  Rheumatology (Oxford)       Date:  2002-03       Impact factor: 7.580

9.  The use of digital artery sympathectomy as a salvage procedure for severe ischemia of Raynaud's disease and phenomenon.

Authors:  T E McCall; D P Petersen; L B Wong
Journal:  J Hand Surg Am       Date:  1999-01       Impact factor: 2.230

10.  Rational use of calcium-channel antagonists in Raynaud's phenomenon.

Authors:  M G Sturgill; J R Seibold
Journal:  Curr Opin Rheumatol       Date:  1998-11       Impact factor: 5.006

View more
  6 in total

Review 1.  New lines in therapy of Raynaud's phenomenon.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

2.  Auricular electroacupuncture reduces frequency and severity of Raynaud attacks.

Authors:  Oliver Schlager; Michael E Gschwandtner; Irene Mlekusch; Karin Herberg; Tanja Frohner; Martin Schillinger; Renate Koppensteiner; Wolfgang Mlekusch
Journal:  Wien Klin Wochenschr       Date:  2011-02-17       Impact factor: 1.704

Review 3.  The diagnosis and treatment of Raynaud's phenomenon: a practical approach.

Authors:  Janet E Pope
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension.

Authors:  D Mukerjee; L B Yap; V Ong; C P Denton; K Howells; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

5.  Acupuncture in subjects with cold hands sensation: study protocol for a randomized controlled trial.

Authors:  Jung-Chul Seo; Hyun-jong Lee; Min-Ah Kwak; Sung-Hoon Park; ImHee Shin; Woo-Sung Yun; Kihyuk Park
Journal:  Trials       Date:  2014-09-04       Impact factor: 2.279

6.  The mechanism of botulinum A on Raynaud syndrome.

Authors:  Yanwen Zhou; Ying Liu; Yunhua Hao; Ya Feng; Lizhen Pan; Wuchao Liu; Bing Li; Libin Xiao; Lingjing Jin; Zhiyu Nie
Journal:  Drug Des Devel Ther       Date:  2018-06-26       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.